{{header
 | author     = 
 | related_author = United States Congress
 | translator = 
 | section    = 
 | previous   = 
 | next       = 
 | year       = 2013
 | month      = 02
 | day        = 13
 | notes      = ''{{USBill|113|S.|315}}'' as introduced
 | categories =
 | portal     =
 | congress   = 113
 | session    = 1
 | title      = Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education (MD–CARE) Amendments of 2013 ( S. 315; 113th Congress)
 | bill       = 315
 | billtype   = s
 | purpose    = To reauthorize and extend the Paul D. Wellstone Muscular Dystrophy Community Assistance, Research, and Education Amendments of 2008.
 | wikipedia  =
}}

{{Center|113th CONGRESS}}


{{Center|1st Session}}


{{Center|S. 315}}


{{Center|IN THE SENATE OF THE UNITED STATES}}


{{Center|February 13, 2013}}


{{Center|
shitburger[[w:|Ms. Klobuchar]] (for herself,
shitburger[[w:|Mr. Wicker]] ,
shitburger[[w:|Mr. Sanders]] ,
shitburger[[w:|Ms. Collins]] ,
shitburger[[w:|Mr. Menendez]] ,
shitburger[[w:|Mr. Isakson]] ,
shitburger[[w:|Ms. Mikulski]] ,
shitburger[[w:|Mr. Leahy]] ,
shitburger[[w:|Mr. Lautenberg]] , and
shitburger[[w:|Mr. Nelson]] ) introduced the following bill; which was read twice and referred to the [[w:United States Senate Committee on Health, Education, Labor, and Pensions|Committee on Health, Education, Labor, and Pensions]] }}


{{Center|A BILL}}

To reauthorize and extend the Paul D. Wellstone Muscular Dystrophy Community Assistance, Research, and Education Amendments of 2008.

=Section 1. Short title=

This Act may be cited as the “Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education (MD–CARE) Amendments of 2013” .

=Sec. 2. Initiative through the Director of the National Institutes of Health=

 Section 404E of the Public Health Service Act( [http://www.law.cornell.edu/uscode/text/42/283g 42 U.S.C. 283g] )is amended—
:(1) in subsection (a)(1)—
::(A) by striking “Muscoskeletal” and inserting “Musculoskeletal” ; and
::(B) by inserting “Becker, myotonic, facioscapulohumeral muscular dystrophy (referred to in this section as “FSHD” ), Congenital muscular dystrophy, Limb-girdle muscular dystrophy,” after “Duchenne,” ;
:(2) in subsection (b)—
::(A) in paragraph (2), by inserting “cardiac and pulmonary function,” after “imaging, genetics,” ; and
::(B) in paragraph (3), by inserting “and sharing of data” after “regular communication” ;
:(3) in subsection (d)—
::(A) in paragraph (2)—
:::(i) in the matter preceding subparagraph (A), by striking “15” and inserting “18” ; and
:::(ii) in subparagraph (A), by striking “children with muscular dystrophy, such as the [[w:United States Department of Education|Department of Education]] ” and inserting “children and adults with muscular dystrophy, such as the [[w:United States Department of Education|Department of Education]] , the [[w:Social Security Administration|Social Security Administration]] , the [[w:Department of Health and Human Services|United States Administration for Community Living]] ” ; and
::(B) in paragraph (4)(B), by inserting “, and shall meet no less than two times per calendar year” before the period;
:(4) in subsection (e)—
::(A) in paragraph (1)—
:::(i) in the matter preceding subparagraph (A), by striking “through the national research institutes” and inserting “through the represented Federal agencies” ; and
:::(ii) in subparagraph (A), by striking “and rehabilitative issues, including studies of the impact of such diseases in rural and underserved communities” and inserting “public resources, and rehabilitative issues, including studies of the impact of such diseases in rural and underserved communities, health economic studies to demonstrate the cost-effectiveness of providing independent living resources and support to patients with various forms of muscular dystrophy, and studies to determine optimal clinical care interventions for adults with various forms of muscular dystrophy” ; and
::(B) in paragraph (2), by adding at the end the following:

<blockquote>
:::(F) The development of clinical interventions to improve the health of adults with various forms of muscular dystrophy.; and
</blockquote>

:(5) in subsection (g), by striking “for the various forms of muscular dystrophy by prioritizing the achievement of the goals related to this topic in the plan under subsection (e)(1)” and inserting “and shall, not later than 6 months after the date of enactment of the Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education (MD–CARE) Amendments of 2013, in coordination with appropriate Federal agencies, including relevant offices within the [[w:Food and Drug Administration|Food and Drug Administration]] and supported by the [[w:National Institutes of Health|National Institutes of Health]] and [[w:United States Department of Defense|Department of Defense]] , develop a plan to expedite the evaluation and approval of emerging therapies and personalized medicines that have the potential to decrease fatal disease progression across the various forms of muscular dystrophy” .

=Sec. 3. Surveillance and research regarding muscular dystrophy=

 Section 317Q of the Public Health Service Act( [http://www.law.cornell.edu/uscode/text/42/247b–18 42 U.S.C. 247b–18] )is amended—
:(1) in the second sentence of subsection (b), by inserting before the period the following: “and ensure that the program captures data from different racial and ethnic populations, and that such data are made publicly available to investigators conducting public or private research on muscular dystrophy” ; and
:(2) in subsection (c), by adding at the end the following: “The [[w:Department of Health and Human Services|Secretary]] shall also foster ongoing engagement and collaboration between the surveillance program and centers of excellence.” .

=Sec. 4. Information and education=

 Section 5(c) of the Muscular Dystrophy Community Assistance, Research and Education Amendments of 2001( [http://www.law.cornell.edu/uscode/text/42/247b–19 42 U.S.C. 247b–19(c)] )is amended by adding at the end the following:

<blockquote>
:(4) Update and widely disseminate existing Duchenne-Becker muscular dystrophy care considerations for pediatric patients, develop and widely disseminate Duchenne-Becker muscular dystrophy care considerations for adult patients, and develop and widely disseminate acute care considerations for all muscular dystrophy populations. The care considerations should build upon existing efforts currently underway for congenital muscular dystrophy, fascioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, and myotonic muscular dystrophy, and incorporate strategies specifically responding to the findings of the national transitions survey of minority, young adult and adult communities of muscular dystrophy patients..
</blockquote>

{{PD-USGov}}
[[Category:Proposed United States federal law]]
[[Category:Proposed United States federal law of the 113th Congress]]
